These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1417 related articles for article (PubMed ID: 21090841)
1. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. Robak T; Robak E BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841 [TBL] [Abstract][Full Text] [Related]
2. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Robak T Curr Opin Investig Drugs; 2009 Jun; 10(6):588-96. PubMed ID: 19513948 [TBL] [Abstract][Full Text] [Related]
4. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Czuczman MS; Gregory SA Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564 [TBL] [Abstract][Full Text] [Related]
5. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma. Forero-Torres A; de Vos S; Pohlman BL; Pashkevich M; Cronier DM; Dang NH; Carpenter SP; Allan BW; Nelson JG; Slapak CA; Smith MR; Link BK; Wooldridge JE; Ganjoo KN Clin Cancer Res; 2012 Mar; 18(5):1395-403. PubMed ID: 22223529 [TBL] [Abstract][Full Text] [Related]
6. Novel humanized anti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions. Nishida M; Teshigawara K; Niwa O; Usuda S; Nakamura T; Ralph P; Newman R; Padlan EA Int J Oncol; 2008 Jun; 32(6):1263-74. PubMed ID: 18497988 [TBL] [Abstract][Full Text] [Related]
7. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells. Klitgaard JL; Koefoed K; Geisler C; Gadeberg OV; Frank DA; Petersen J; Jurlander J; Pedersen MW Br J Haematol; 2013 Oct; 163(2):182-93. PubMed ID: 23927424 [TBL] [Abstract][Full Text] [Related]
8. Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma. Zhang H; Song L; Ye H; Hu L; Liang W; Liu D Cell Physiol Biochem; 2013; 32(3):645-54. PubMed ID: 24022075 [TBL] [Abstract][Full Text] [Related]
9. Novel CD20 monoclonal antibodies for lymphoma therapy. Cang S; Mukhi N; Wang K; Liu D J Hematol Oncol; 2012 Oct; 5():64. PubMed ID: 23057966 [TBL] [Abstract][Full Text] [Related]
10. BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties. Nishida M; Uematsu N; Kobayashi H; Matsunaga Y; Ishida S; Takata M; Niwa O; Padlan EA; Newman R Int J Oncol; 2011 Feb; 38(2):335-44. PubMed ID: 21152859 [TBL] [Abstract][Full Text] [Related]
11. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Bowles JA; Wang SY; Link BK; Allan B; Beuerlein G; Campbell MA; Marquis D; Ondek B; Wooldridge JE; Smith BJ; Breitmeyer JB; Weiner GJ Blood; 2006 Oct; 108(8):2648-54. PubMed ID: 16825493 [TBL] [Abstract][Full Text] [Related]
12. Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia. Robak T Future Oncol; 2013 Jan; 9(1):69-91. PubMed ID: 23252565 [TBL] [Abstract][Full Text] [Related]
13. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia. Robak T Curr Cancer Drug Targets; 2008 Mar; 8(2):156-71. PubMed ID: 18336199 [TBL] [Abstract][Full Text] [Related]
14. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Rossi EA; Goldenberg DM; Cardillo TM; Stein R; Wang Y; Chang CH Cancer Res; 2008 Oct; 68(20):8384-92. PubMed ID: 18922911 [TBL] [Abstract][Full Text] [Related]
15. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696 [TBL] [Abstract][Full Text] [Related]
16. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Bornstein GG; Quéva C; Tabrizi M; van Abbema A; Chavez C; Wang P; Foord O; Ahluwalia K; Laing N; Raja S; Wen S; Green LL; Yang X; Webster C; Stewart R; Blakey D Invest New Drugs; 2010 Oct; 28(5):561-74. PubMed ID: 19626278 [TBL] [Abstract][Full Text] [Related]
17. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Cheson BD J Clin Oncol; 2010 Jul; 28(21):3525-30. PubMed ID: 20458041 [TBL] [Abstract][Full Text] [Related]
18. Optimization of anti-CD20 humanized antibody hu8E4 by site-directed mutation based on epitope analysis. Chen Y; Chen L; Lu Q; Meng Y; Wang C; Wang L; Wang H; Yu X; Zhang Y; Zhao L; Li B; Guo Y Biochem Biophys Res Commun; 2015 Apr; 459(4):617-22. PubMed ID: 25749344 [TBL] [Abstract][Full Text] [Related]
19. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity. Natsume A; Shimizu-Yokoyama Y; Satoh M; Shitara K; Niwa R Cancer Sci; 2009 Dec; 100(12):2411-8. PubMed ID: 19758394 [TBL] [Abstract][Full Text] [Related]
20. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]